Prostate Cancer Clinical Trials in Pittsburgh

Showing 161-180 of 332 trials

A Study of CART-PSMA-TGFβRDN in Patients With Metastatic Castration Resistant Prostate Cancer

NCT04227275

Multi-center, open-label, Phase 1 study of the safety, tolerability and feasibility of dosing patients harboring metastatic castration resistant prostate cancer (mCRPC) with genetically modified autologous T cells (CART-PSMA-TGFβRDN cells) engineered to express a chimeric antigen receptor (CAR) capable of recognizing the tumor antigen prostate-specific membrane antigen (PSMA) and activating the T cell.

Metastatic Castration-resistant Prostate Cancer

Tceleron Therapeutics, Inc.16 participantsStarted Nov 2019

Tampa, Florida, United States • Kansas City, Kansas, United States • St Louis, Missouri, United States +6 more locations

COMPLETEDPhase 211 miles

Immunotherapy For Men With Objective Disease Progression On Protocol D9902 Part B (NCT00065442)

NCT00849290

This is an open label, Phase 2 trial of APC8015F immunotherapy in men with objective disease progression on protocol D9902 part B (NCT00065442)

Metastatic Androgen Independent Prostate Cancer

Dendreon113 participantsStarted Apr 2004

Los Angeles, California, United States • Los Angeles, California, United States • Sacramento, California, United States +55 more locations

A Study of CART-PSMA-TGFβRDN in Patients With Metastatic Castration Resistant Prostate Cancer

Immunotherapy For Men With Objective Disease Progression On Protocol D9902 Part B (NCT00065442)

Prostate Cancer Trials in Other Cities

Safety and Tolerability Study of ISIS EIF4E Rx in Combination With Docetaxel and Prednisone (CRPC)

Efficacy Evaluation of VERU-111 for mCRPC in Patients Who Have Failed at Least One Androgen Receptor Targeting Agent

A Dose Escalation and Expansion Study of TRX518 in Combination With Cyclophosphamide Plus Avelumab in Advanced Solid Tumors

A Study of PRT2527 in Participants With Advanced Solid Tumors

COMbination of Bipolar Androgen Therapy and Nivolumab

A Parallel Arm Phase 1b/2a Study of DKN-01 as Monotherapy or in Combination With Docetaxel for the Treatment of Advanced Prostate Cancer With Elevated DKK1

Study of Ipatasertib or Apitolisib With Abiraterone Acetate Versus Abiraterone Acetate in Participants With Castration-Resistant Prostate Cancer Previously Treated With Docetaxel Chemotherapy

A Study of FT-7051 in Men With MCRPC

Exploratory PK and Imaging Study of PSMA-Targeted Trillium Compounds and PTI-122 in Metastatic Prostate Cancer

A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors

CASCARA: Castration Sensitive Carboplatin, Cabazitaxel and Abiraterone

A Study Evaluating the Safety, Pharmacokinetics and Efficacy of Ipatasertib Administered in Combination With Rucaparib in Participants With Advanced Breast, Ovarian Cancer, and Prostate Cancer.

A Study Evaluating the Safety, Pharmacokinetics, and Clinical Effects of Intravenously Administered PT-112 Injection in Subjects With Advanced Solid Tumors and Subsequent Dose Expansion Cohorts

ATR Inhibitor Elimusertib (BAY1895344) Plus Niraparib Phase 1b Study in Advanced Solid Tumors and Ovarian Cancer

Identification of Clinically Insignificant or Significant Prostate Cancer With the miR Scientific Sentinel™ Platform

Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors.

A JNJ-56021927 (ARN-509; Apalutamide) QT/QTc Study

Telomere Associated Variables (TAVs) in Prostate Cancer

Other Conditions in Pittsburgh